No direct correlation with adverse events found for bevacizumab treatment of ROP

August 2015
Ocular Surgery News;8/10/2015, Vol. 33 Issue 15, p16
Academic Journal
The article discusses research which showed no adverse effects on the use of intravitreal bevacizumab in treating preterm infants of retinopathy of prematurity.


Related Articles

  • Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Eun Chung; Ji Kim; Hyun Ahn // Graefe's Archive of Clinical & Experimental Ophthalmology;Nov2007, Vol. 245 Issue 11, p1727 

    Abstract Background  This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive zone I retinopathy of prematurity (ROP). Methods  A male patient, born at 25 weeks gestation with a birth...

  • Bevacizumab in colorectal cancer: profile report. Adis International Limited // Drugs & Therapy Perspectives;May2005, Vol. 21 Issue 5, p5 

    Focuses on the effectiveness of bevacizumab, a recombinant humanised monoclonal antibody directed against vascular endothelial growth factor, in treating colorectal cancer. Dosage of bevacizumab administered to patients; Adverse events of bevacizumab; Effect of the drug on the gastrointestinal...

  • Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity. Kim, Rebecca; Yu Cheol Kim // Journal of Ophthalmology;2014, p1 

    Purpose. To report the results of the posterior pole sparinglaser photocoagulation combined with intravitreal bevacizumab injection (IVB) in retinopathy of prematurity (ROP). Methods. A retrospective chart review of premature babies with ROP, all of whom received laser photocoagulation with IVB....

  • Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A Cost-effectiveness Review. Nwanze, Chukwuemeka C.; Akinwale, Abumere; Adelman, Ron A. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p29 

    Objective: To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered. Methods: A...

  • Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Cortes, J.; Calvo, V.; Ramírez-Merino, N.; O'Shaughnessy, J.; Brufsky, A.; Robert, N.; Vidal, M.; Muñoz, E.; Perez, J.; Dawood, S.; Saura, C.; Di Cosimo, S.; González-Martín, A.; Bellet, M.; Silva, O. E.; Miles, D.; Llombart, A.; Baselga, J. // Annals of Oncology;May2012, Vol. 23 Issue 5, p1130 

    Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse...

  • Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Kusaka, S.; Shima, C.; Wada, K.; Arahori, H.; Shimojyo, H.; Sato, I.; Fujikado, T. // British Journal of Ophthalmology;Nov2008, Vol. 92 Issue 11, p1450 

    Aim: The aim of the study was to evaluate the short-term efficacy of intravitreal injections of bevacizumab for severe retinopathy of prematurity (ROP). Methods: A retrospective chart review was conducted of 23 consecutive eyes (stage 3, three eyes; 4A, 18 eyes; 4B, two eyes) of 14 patients with...

  • Bevacizumab plus chemotherapy did not extend survival in triple-negative breast cancer.  // Hem/Onc Today;10/10/2013, Vol. 14 Issue 19, p26 

    The article discusses a phase 3 multicenter study which found that patients with triple-negative breast cancer who underwent bevacizumab treatment and chemotherapy experienced comparable survival but higher rates of adverse events compared with those who underwent chemotherapy alone.

  • Outcomes of Retinopathy of Prematurity Screening at a Tertiary Government Hospital. Mina-Alvarez, Emmeline R.; Ventura, Ricardo H. // Philippine Journal of Ophthalmology;Jul/Dec2013, Vol. 38 Issue 2, p109 

    Objective: To determine the outcomes of retinopathy of prematurity (ROP) screening at a tertiary government hospital. Method: Medical records of premature infants who underwent ROP screening at a tertiary government hospital from January 2008 to July 2012 were obtained. Eventual outcomes of the...

  • Physicians consider adopting intravitreal bevacizumab as routine treatment for ROP.  // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p1 

    The article discusses a debate among U.S. physicians regarding the potential adoption of intravitreal bevacizumab as retinopathy of prematurity (ROP) treatment in 2011.

  • Retinopathy of prematurity. Jing Chen; Lois Smith // Angiogenesis;Jun2007, Vol. 10 Issue 2, p133 

    Abstract  Retinopathy of prematurity (ROP) is a common blinding disease in children in the developed world despite current treatment, and is becoming increasingly prevalent in the developing world. ROP progresses in two phases. The first phase begins with delayed retinal vascular growth...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics